Anocca Presents Data at ESMO Congress on Preclinical Development of its TCR-T Cell Therapies for Cancer
09 September 2024 - 8:00AM
Anocca AB, a leading T cell receptor-engineered T cell (TCR-T)
cellular therapeutics company, announces it will present its novel
platform approach to therapeutic TCR discovery and preclinical data
for its lead TCR-T cell therapy product at the European Society of
Medical Oncology (ESMO) Congress 2024.
Category: Investigational
ImmunologyPoster title: Preclinical development of
TCR-modified T-cell therapies against mutated
KRAS Date and time: 9am-5pm
local time on Saturday 14
SeptemberLocation: Hall 6, Fira Barcelona
Gran Via, Barcelona,
SpainLink: https://tinyurl.com/4n67775y
The poster introduces Anocca’s programmable cellular technology
platform that systematically recreates human T-cell biology to map
T-cell targets and build TCR libraries for the generation of
validated therapeutic TCRs, and describes the preclinical
development of its lead therapeutic TCR-T product targeting
KRAS-G12V that is being progressed into planned clinical trials.
KRAS is the most frequently mutated oncogene and associated with
highly fatal cancers of the pancreas, lung and colon. Due to its
intrinsic properties, effective targeting strategies have
historically been elusive, presenting significant unmet need.
Hugh Salter, Chief Scientific Officer at Anocca, and presenter
of the poster, added, "We are excited to present our technology
platform and the details of our lead TCR-T product at ESMO. Our
research demonstrates that TCR-T cell therapies offer a precise
route, via autologous modification of patient CD8 cells, to
directly address foundational driver events in solid tumours.”
Members of the company’s management team, including CSO Hugh
Salter, CMO Zahid Bashir, Clinical Science Lead Rehab Alnabhan, and
Director of Clinical Operations Sheila Forsman, will be available
for meetings at ESMO.
About AnoccaAnocca is a fully integrated
biopharmaceutical company developing libraries of T cell
receptor-engineered T cell (TCR-T) therapies to redefine the
treatment of solid tumours and other difficult to treat diseases,
including infectious and autoimmune diseases. Its proprietary
technologies have been designed to vastly expand TCR-T cell therapy
development, allowing the systematic generation of treatments for
the broadest patient populations that equip the immune system
against the most difficult to treat solid tumours.
Anocca operates an advanced research and development
infrastructure, underpinned by a custom software ecosystem and
in-house clinical manufacturing and process development facilities.
Its unique discovery platform uses programmable human cells to
recreate and manipulate T cell immunity.
Follow Anocca on LinkedIn and visit our website
Media Inquiries
Anocca ABwww.anocca.com/contact
Scius Communications (for Anocca AB)Katja
StoutTel: +44 7789 435 990katja@sciuscommunications.com
Daniel GoochTel: +44 7747 875
479daniel@sciuscommunications.com